Commercial AvailabilityZEVASKYN is now officially commercially available in the U.S. after the activation of Ann & Robert H. Lurie Children’s Hospital of Chicago as the first of five qualified treatment centers.
Earnings ForecastAbeona anticipates becoming profitable in early 2026, with projections indicating potential profitability before the end of this year depending upon the trajectory of the ZEVASKYN launch.
Financial StabilityAbeona announced the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155M, providing sufficient cash for more than two years of operating expenses.